| Vol. 10.29 – 26 July, 2022 |
| |
|
|
| Scientists described a system, called BEHAV3D, developed to study the dynamic interactions of immune cells and patient cancer organoids by means of imaging and transcriptomics. [Nature Biotechnology] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers described a patient with inherited T-bet deficiency and largely normal humoral immunity including intact somatic hypermutation, affinity maturation, and memory B cell formation in vivo, and B cell differentiation into Ig-producing plasmablasts in vitro. [Science Immunology] |
|
|
|
| Using an in vitro culture system modeling human T cell dysfunction and exhaustion in triple-negative breast cancer, the authors found that hypoxia suppressed immune effector gene expression, including in T and NK cells, resulting in immune effector cell dysfunction and resistance to immunotherapy. [Nature Communications] |
|
|
|
| Investigators developed two different types of nanocarrier based on bacterial membrane materials, which employed genetically engineered outer membrane vesicles, or hybrid membrane vesicles containing bacterial cytoplasmic membrane, respectively. [Nature Protocols] |
|
|
|
| The authors reported that interferon-β exerted partially overlapping, but also cooperative actions with aspirin-triggered 15-epi-lipoxin A4 and 17-epi-resolvin D1 to counter TLR9-generated cues to regulate neutrophil apoptosis and phagocytosis in human neutrophils. [Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| To explore the therapeutic utility of switchable CAR-T cells targeting the receptor tyrosine kinase ROR1, a panel of switches based on ROR1-targeting Fabs with different epitopes and affinities was compared in in vitro and in vivo models of ROR1-expressing cancers. [Oncogene] |
|
|
|
| Investigators found that FOXM1 regulated reactive oxygen species (ROS) levels in neutrophils and inhibition of FOXM1 resulted in increased ROS leading to neutrophil extracellular trap (NET) formation. [EMBO Reports] |
|
|
|
| The authors performed an integrated study based on biological experiments and multi-dimensional data types, including genomic, transcriptomic, and clinical immune checkpoint blockade-treated melanoma cohorts from public databases. [British Journal of Cancer] |
|
|
|
| Plasma collected from children with B cell acute lymphoblastic leukemia with measurable residual disease after induction chemotherapy showed differential cytokine expression while single-cell RNA-sequencing revealed the expression of genes associated with immune exhaustion in immune cell subsets. [Scientific Reports] |
|
|
|
| Researchers studied synovial biopsies captured from untreated rheumatoid arthritis patients at the time of diagnosis and found that the tissue architecture implicated both local B cell maturation via T cell help and plasma cell survival niches with a strong CXCL12–CXCR4 axis. [Scientific Reports] |
|
|
|
| Scientists compared the effects of different preparations of IgG anti-IgE obtained from patients with atopic dermatitis with rabbit IgG anti-IgE on the release of preformed and lipid mediators from cardiac mast cells. [Clinical and Experimental Medicine] |
|
|
|
|
| Investigators describe the various approaches to augment NK cell cytotoxicity and longevity, evaluate challenges and opportunities, and reflect on how lessons learned from the clinic will guide the design of next-generation NK cell products that will address the unique complexities of each cancer. [Nature Reviews Cancer] |
|
|
|
| The authors outline hallmarks of tumor-associated macrophages and discuss the emerging mechanisms that contribute to their pathophysiological adaptations and the vulnerabilities that provide attractive targets for therapeutic exploitation in cancer. [Nature Immunology] |
|
|
|
| Scientists outline our current understanding of normal immune aging, describe the mechanism of immunometabolic dysfunction in accelerating this process, and propose the role these processes are playing in the pathogenesis of multiple myeloma. [Leukemia] |
|
|
|
|
| Sosei Group Corporation and Cancer Research UK announced the signing of an agreement to bring Sosei Heptares’ cancer immunotherapy drug candidate into a first-in-human trial. [Sosei Group Corporation] |
|
|
|
| F-star Therapeutics, Inc. announced that it has entered into a license agreement with Takeda. F-star will grant Takeda a license to research, develop, and commercialize a bispecific antibody against an immuno-oncology target using F-star’s proprietary Fcab™ and mAb2™ platforms. [F-star Therapeutics, Inc.] |
|
|
|
| Artizan Biosciences, Inc. announced that it has entered into a multi-year research collaboration with the University Medical Center Utrecht in The Netherlands and Microviable Therapeutics SL to explore the role that gut microbiota may have in immune checkpoint inhibitor therapies for patients with cancer. [Artizan Biosciences, Inc.] |
|
|
|
|
| August 28 – September 2, 2022 Asheville, North Carolina, United States |
|
|
|
|
|
| Gilead Sciences, Inc. – Foster City, California, United States |
|
|
|
| Genentech, Inc. – South San Francisco, California, United States |
|
|
|
| Icahn School of Medicine at Mount Sinai – New York, New York, United States |
|
|
|
| University Hospital of Muenster – Münster, Germany |
|
|
|
| Baylor College of Medicine – Houston, Texas, United States |
|
|
|
|